Approaching the era of personalised therapy for liver cancer?
Mené sur 108 patients atteints d'un carcinome hépatocellulaire avancé et d'une cirrhose (score de Child-Pugh : A), cet essai de phase II évalue, du point de vue du délai avant progression, le tivantinib, un inhibiteur de MET par voie orale, en traitement de deuxième ligne
Results from recent phase 3 trials of anti-angiogenic drugs for advanced hepatocellular carcinoma have been disappointing. However, early results of investigations into MET inhibitors in this setting have begun to emerge and could provide tangible hope. In The Lancet Oncology, Armando Santoro and colleagues present findings of a randomised phase 2 study of tivantinib versus placebo in patients with advanced hepatocellular carcinoma whose cancer had progressed on a previous line of therapy. Cabozantinib is also being assessed in the same setting...
The Lancet Oncology , commentaire en libre accès, 2011